<DOC>
	<DOCNO>NCT01073436</DOCNO>
	<brief_summary>To investigate whether patient chronic-phase chronic myeloid leukemia ( CP-CML ) previously treat interferon-alpha ( IFN ) presently tyrosine kinase inhibitor ( TKI ) ( imatinib mesylate , dasatinib , nilotinib ) achievement complete cytogenetic least major molecular remission , able discontinue therapy maintain durable remission . Relapse-free survival ( RFS ) rate 1 year discontinuation TKI measurement objective .</brief_summary>
	<brief_title>Discontinuation Imatinib Mesylate Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Patients must diagnosis Philadelphia chromosome positive ( Ph+ ) chronic myeloid leukemia chronic phase . 2 . Patients must receive prior therapy interferonalpha CML , period least 2 year , achieve least partial cytogenetic response therapy , define 1 % 34 % Ph+ cell metaphase , present bone marrow . 3 . Patients must actively receive treatment CML TKI ( imatinib mesylate , dasatinib , nilotinib ) . If patient receive dasatinib nilotinib , reason imatinibresistant CML . 4 . Patients must ongoing complete hematologic response ( CHR ) TKI , define follow : WBC ≤ 10 x 109/L . Platelet count &lt; 450,000 x 109/L . No blast promyelocytes peripheral blood . No evidence diseaserelated symptom extramedullary disease , include liver spleen . 5 . Patients must complete cytogenetic response ( CCyR ) TKI minimum one year lead enrollment . Complete cytogenetic response define 0 % Ph+ cell metaphase , bone marrow and/or negative peripheral blood FISH analysis BCR/ABL gene fusion , ongoing CCyR must confirm bone marrow aspirate cytogenetics and/or peripheral blood FISH BCR/ABL within 4 week discontinue therapy . 6 . Patients must least major molecular remission TKI minimum 1 year , present 2 consecutive analysis , perform least 3 month apart , 6 12 month lead enrollment . Major molecular remission define ≥ 3 log reduction standard baseline value ( equivalent BCRABL/ABL ≤ 0.1 % ) BCR/ABL transcript quantitative RTPCR perform peripheral blood bone marrow aspirate . Complete molecular remission define negative quantitative RTPCR ( QPCR ) analysis BCR/ABL , present 2 consecutive analysis , perform least 3 month apart , 6 12 month lead enrollment . 7 . Patients must eighteen year age old 8 . Patients must ECOG performance status 02 ( Appendix 13.1 ) 9 . All patient must inform investigational nature study standard alternative therapy . All patient must sign give write informed consent accordance institutional federal guideline . 1 . Patients prior progression CML accelerate phase blast crisis . 2 . Patients previously undergone hematopoietic stem cell transplantation . 3 . Patients receive dasatinib nilotinib due prior history imatinibresistant CML . 4 . Patients history noncompliance medical regimen consider potentially unreliable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>diagnosis Ph+ ) CML chronic phase .</keyword>
	<keyword>prior therapy interferon-alpha least 2 year , achieve least partial cytogenetic response</keyword>
	<keyword>receive TKI ( imatinib mesylate , dasatinib , nilotinib )</keyword>
	<keyword>WBC ≤ 10 x 109/L .</keyword>
	<keyword>Platelet count &lt; 450,000 x 109/L .</keyword>
	<keyword>No blast promyelocytes peripheral blood .</keyword>
	<keyword>No evidence disease-related symptom extramedullary disease</keyword>
	<keyword>complete cytogenetic response ( CCyR ) TKI minimum 1 yr</keyword>
	<keyword>major molecular remission TKI minimum 1 yr</keyword>
	<keyword>18 year age old</keyword>
	<keyword>ECOG performance status 0-2 ( Appendix 13.1 )</keyword>
	<keyword>Informed Consent</keyword>
</DOC>